In fact, thromboembolism biomarkers in patients with cancer were reviewed recently (Gervaso et al. 2021) and apart from platelet and leukocyte counts, the authors list tissue factor (Coagulation Factor III), d-dimers, soluble P-selectin and CRP, overlapping with the markers of Table 1. This evidence concerns the gene SELP and cancer.